Weight-loss injections: how they actually work

GLP-1 is a hormone your gut already releases when you eat. It signals the pancreas to release insulin, slows how quickly the stomach empties, and acts on the parts of the brain that register fullness. The medications in this class imitate that signal and hold it steady rather than letting it spike and fade.

The practical result is that meals finish sooner and stay finishing. For many people the more striking change is quieter: the constant background negotiation about food, sometimes called food noise, drops away. People describe being able to leave half a plate without it costing them anything.

This matters because it reframes what the medication is. It is not burning anything. It is not blocking absorption. It is changing an appetite signal that was, in many people, working against them. That is why the results are real and also why the habits built during treatment decide what happens afterwards.

Some of these medicines act on a second hormone pathway alongside GLP-1. That difference is part of how we choose between them, and it is covered in the article on choosing between semaglutide and tirzepatide.

Appetite suppression creates an opportunity, not an outcome. Eating far less without attention to what is in it produces weight loss alongside poor protein intake, low fibre, missed micronutrients and lost muscle. That is a worse result wearing the appearance of a better one.

The targets we set are unglamorous: adequate protein at every meal, fibre and fluid to manage the constipation the medication reliably causes, and resistance training two or three times a week. Patients who do those three things keep more muscle, feel better during treatment, and hold the result afterwards.

We also plan for the end of treatment at the beginning of it. Appetite returns when the medication stops. If nothing else changed during the treated months, weight returns with it, and that experience is demoralising in a way that makes the next attempt harder. The months on treatment are when the habits are cheap to build, because the appetite pressure is off.

These medicines are not appropriate for everyone. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 rules them out. A history of pancreatitis, significant gallbladder disease, severe gastrointestinal disease, current pregnancy or plans for pregnancy all change the conversation.

Compounded versions sold outside the regulated supply chain are a real risk and the U.S. Food and Drug Administration has published warnings about them. Dosing errors from unfamiliar concentrations and unverified contents are the reported problems. We prescribe approved products through pharmacies.

Monitoring is part of the treatment rather than an extra. That means reviewing tolerance, checking that nutrition is holding, and looking for the uncommon problems early. Anyone offering this by questionnaire with no follow-up is selling access to a prescription, not medical care.